CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <\/p>\n
Foundation Medicine, Inc. (FMI) today announced that results from a 24-month, multi-institution collaboration demonstrating the analytic validation of its cancer genomic profiling assay, FoundationOne, were published in the current online edition of Nature Biotechnology.1 FoundationOne is a comprehensive, next-generation sequencing (NGS) based test used to characterize all classes of molecular alterations (base substitutions, short insertions and deletions (indels), copy number alterations and select rearrangements) across 287 cancer-related genes from routine formalin-fixed, paraffin-embedded (FFPE) clinical specimens. The publication also describes clinical application of this assay across 2,221 consecutive patient cases. <\/p>\n
Comprehensive genomic testing is becoming critical to deliver the most effective care for patients with cancer. However, analytic validation of NGS-based tests presents a challenge to clinical application due to the fact that thousands of potential variants may be detected, and most have no gold standard with which to compare. This publication is the first to apply and extend the guidelines established by the Next-Generation Sequencing: Standardization of Clinical Testing (Nex-StoCT) workgroup2 to validate a clinical sequencing-based assay for cancer, therefore setting the standard for validation of targeted NGS in cancer. <\/p>\n
Clinical cancer care is undergoing a fundamental shift toward treating patients based on the specific molecular drivers of their disease, and a sequencing-based diagnostic assay that comprehensively and accurately characterizes the genomic alterations occurring within an individuals tumor is essential for the implementation of this therapeutic strategy, stated Lajos Pusztai, M.D., co-director of the Cancer Genetics and Genomics Research Program at Yale Cancer Center and co-author of the study. This study is instrumental in establishing the technical validity of next-generation sequencing in the clinic and enables the practice of precision medicine wherein the molecular characterization of a patients tumor informs the patients individual treatment. <\/p>\n
Foundation Medicine assessed the accuracy and precision of FoundationOne using reference samples of pooled cell lines and hundreds of clinical cancer specimens with diagnostic testing results generated by established clinical assays. FoundationOne was found to be highly accurate in identifying genomic alterations, including sensitivity greater than 99% for detection of base substitutions, 98% for detection of insertions and deletions, and greater than 95% for detection of copy number alterations, while maintaining greater than 99% specificity. Application of FoundationOne to 2,221 clinical cases revealed clinically actionable alterations in 76% of tumor samples, three times the number of actionable alterations detected by other currently available diagnostic tests. Alterations are defined as clinically actionable if linked to an FDA approved targeted therapy in the tumor under study or another solid tumor, a known or suspected contraindication to a given therapy, or an open clinical trial for which the alteration confers patient eligibility. <\/p>\n
FoundationOne was proven to have the sensitivity and specificity required for routine clinical practice, and it identified more than three times the clinically actionable alterations that are identifiable using a collection of six commercially available and commonly used diagnostic tests, including the other most common NGS-based tests. This comprehensive approach directly translates into more treatment options for patients, said Michael J. Pellini, M.D., president and chief executive officer of Foundation Medicine. We believe this study establishes the standard for analytic performance that is required for patients with cancer to benefit from the clinical application of next-generation sequencing of their tumors. <\/p>\n
About Foundation Medicine <\/p>\n
Foundation Medicine (FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patients unique cancer. The companys initial clinical assay, FoundationOneTM, is a fully informative genomic profile to identify a patients individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicines molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http:\/\/www.FoundationMedicine.com<\/a> or follow Foundation Medicine on Twitter (@FoundationATCG). <\/p>\n Foundation Medicine is a registered trademark, and FoundationOneTMis a trademark of Foundation Medicine, Inc. <\/p>\n Cautionary Note Regarding Forward-Looking Statements <\/p>\n <\/p>\n Go here to see the original: <\/p>\n Foundation Medicine Announces Publication of Analytic Validation Study of FoundationOne\u2122 in Nature Biotechnology<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. (FMI) today announced that results from a 24-month, multi-institution collaboration demonstrating the analytic validation of its cancer genomic profiling assay, FoundationOne, were published in the current online edition of Nature Biotechnology.1 FoundationOne is a comprehensive, next-generation sequencing (NGS) based test used to characterize all classes of molecular alterations (base substitutions, short insertions and deletions (indels), copy number alterations and select rearrangements) across 287 cancer-related genes from routine formalin-fixed, paraffin-embedded (FFPE) clinical specimens. The publication also describes clinical application of this assay across 2,221 consecutive patient cases. Continue reading